Empowering Breast Surgeons: A Call for Collective Action
As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
Join us at our annual in-person conference to hear expert speakers on LGBTIQ+ cancer care and make amazing networking connections!
Trial of tucatinib and trastuzumab also showed benefits for HER2-mutated breast cancer: Thursday 24 October 2024, Barcelona, Spain: Drugs designed to target HER2-postive breast cancer…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Dissection of genotype–phenotype relationships in hemophilia B (HB) is particularly relevant for challenging (mild HB) or for HB-associated but unclassified factor (F)IX missense variants.
The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.
Joshua K. Sabari, MD, discusses the expected PFS of 3 to 6 months and OS of 6 to 12 months for second- or third-line therapy…
Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.
Cadonilimab plus chemotherapy, with or without bevacizumab, could be a safe and effective treatment option, according to researchers.